ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.732,62
0,27%
S&P 500
5.307,01
-0,27%
Dow Jones
39.671,04
-0,51%
Euro vs US Dollar
1,08485
0,22%
Bitcoin
69.601,01
0,72%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Hoth Therapeutics Inc (HOTH)

  7. Hoth Therapeutics Inc (HOTH) News

HOTH

Hoth Therapeutics (HOTH)

Hoth Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:HOTH
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202422h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
01/05/202414h00PR Newswire (US)Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024NASDAQ:HOTHHoth Therapeutics Inc
27/03/202419h00PR Newswire (US)Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsNASDAQ:HOTHHoth Therapeutics Inc
27/03/202413h27PR Newswire (US)Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentNASDAQ:HOTHHoth Therapeutics Inc
19/03/202413h21PR Newswire (US)Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZNASDAQ:HOTHHoth Therapeutics Inc
29/02/202414h38PR Newswire (US)Hoth Therapeutics Retains Venable LLP to Expand Its Patent PortfolioNASDAQ:HOTHHoth Therapeutics Inc
26/02/202414h11PR Newswire (US)Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
13/02/202417h45PR Newswire (US)Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024NASDAQ:HOTHHoth Therapeutics Inc
18/01/202414h20PR Newswire (US)Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill PatientsNASDAQ:HOTHHoth Therapeutics Inc
09/01/202421h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
08/01/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/01/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/01/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/01/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
27/12/202314h21PR Newswire (US)Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of MiamiNASDAQ:HOTHHoth Therapeutics Inc
05/12/202314h33PR Newswire (US)Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling StudiesNASDAQ:HOTHHoth Therapeutics Inc
14/11/202314h37PR Newswire (US)Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KITNASDAQ:HOTHHoth Therapeutics Inc
13/11/202322h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
10/11/202314h00PR Newswire (US)Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023NASDAQ:HOTHHoth Therapeutics Inc
05/10/202316h03PR Newswire (US)Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug DiscoveryNASDAQ:HOTHHoth Therapeutics Inc
05/10/202314h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
02/10/202314h33PR Newswire (US)FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
15/09/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
15/09/202320h38PR Newswire (US)Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:HOTHHoth Therapeutics Inc
14/09/202323h24Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOTHHoth Therapeutics Inc
13/09/202319h43PR Newswire (US)Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:HOTHHoth Therapeutics Inc
13/09/202314h16PR Newswire (US)Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid LeukemiaNASDAQ:HOTHHoth Therapeutics Inc
11/09/202316h04PR Newswire (US)Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
06/09/202314h12PR Newswire (US)Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexaNASDAQ:HOTHHoth Therapeutics Inc
21/08/202323h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HOTH

Kürzlich von Ihnen besucht

NYSE
DIS
Walt Disney
NYSE
XOM
Exxon Mobil
AMEX
SPY
SPDR S&P 500
DBI
TDXP
Tec DAX
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
D7G
Nel ASA
FX
EURGBP
Euro vs Sterling
CCOM
US100
US Tech 100
USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
FX
EURUSD
Euro vs US Dollar
TG
BAYN
Bayer
TG
TUI1
Tui
TG
MBG
MercedesBenz
NASDAQ
NVDA
NVIDIA
DBI
SDXP
SDAX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten